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The Dombrock blood group system: a review
C. Lomas-Francis and M.E. Reid
The Dombrock blood group system (Do) consists of two an-
tithetical antigens (Doa and Dob) and five antigens of high 
prevalence (Gya, Hy, Joa, DOYA, and DOMR). Do antigens are 
carried on the Dombrock glycoprotein, which is attached to 
the RBC membrane via a glycosylphosphatidylinositol linkage. 
The gene (DO, ART4) encoding the Do glycoprotein, located 
on the short arm of chromosome 12, has been cloned and se-
quenced, allowing the molecular basis of the various Do phe-
notypes to be determined. Doa and Dob have a prevalence that 
makes them useful as genetic markers; however, the paucity 
of reliable anti-Doa and anti-Dob has prevented this potential 
from being realized. The ease with which these antigens can be 
predicted by analysis of DNA opens the door for such studies 
to be carried out. Anti-Doa and anti-Dob are rarely found as 
a single specificity, but they have been implicated in causing 
hemolytic transfusion reactions. This review is a synthesis of 
our current knowledge of the Dombrock blood group system. 
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The Dombrock (Do) blood group system illustrates the value of different methods for the ad-
vancement of knowledge. Classical he-
magglutination showed certain charac-
teristics of the antigens and antibodies, 
a relationship of Hy to Gya, and the fact 
that the Gy(a–) phenotype was the null 
of the Dombrock blood group system. 
Immunoblotting provided a tool to al-
low further characterization of the 
Dombrock glycoprotein, including the 
fact that it is linked to the RBC mem-
brane by a glycosylphosphatidylinosi-
tol (GPI) anchor. In silico analysis 
aided in cloning the DO gene and led 
to PCR-based assays not only to iden-
tify the nucleotide changes associated 
with the antigens but also to screen for 
antigen-negative donors and identify 
new alleles. Transfection and hybrido-
ma technology has been used for the 
production of monoclonal antibodies to 
Do, and DNA array technology provides 
a means to do high-throughput testing 
of donor blood. This review summarizes the understanding 
of the Dombrock blood group system that has evolved as 
methods were developed and applied.
History
 Anti-Doa was identifi ed in 1965,1 and anti-Dob, which 
recognizes the antithetical antigen, was described 8 years 
later.2 These two antibodies defi ne three phenotypes, the 
prevalence of which differs in various ethnic groups (Ta-
ble 1). For populations other than Whites,2,4 studies have 
been restricted to testing with anti-Doa, and thus the num-
bers given for Do(a–b+) in Table 1 are calculated from the 
prevalence given for  Doa.4–6 Doa and Dob were placed in the 
Dombrock blood group system (DO; 014) by the ISBT Work-
ing Party on Terminology for Red Cell Surface Antigens in 
1985.7
Review
Table 1. The Dombrock blood group system
RBC
phenotype
Reactivity with anti- Occurrence (%) in
Doa Dob Gya Hy Joa Whites Blacks Japanese Thai Chinese
Do(a+b–) + 0 + + + 18 11 1.5 0.5
Do(a+b+) + + + + + 49 44 22 13
Do(a–b+) 0 + + + + 33 45 76.5 86.5
Gy(a–) 0 0 0 0 0 Rare Rare* Rare Not 
found 
Rare†










+ wk 0 Not 
found




*One Gy(a–) Black proband has been reported.3
†One Gy(a–) Chinese proband has been found (unpublished data).
‡RBCs will most often be Do(b–) when the Do glycoprotein is encoded by JO/JO but Do(b+W) 
when encoded by HY/JO.
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 The high-prevalence antigens Gregory (Gya) and Hol-
ley (Hy), described independently in 19678,9 were shown to 
be phenotypically related. RBCs from Caucasians with the 
Gy(a–) phenotype are Hy–, and RBCs from Black people 
of African descent with the Hy– phenotype are Gy(a+w).10 
On the basis of this observation, Gya and Hy were upgrad-
ed from the ISBT Series of High Incidence Antigens to the 
Gregory Collection (206) (Table 2).11 Gya and Hy were shown 
to be located on the same glycoprotein by immunoblotting 
in 1991.12
 The high-prevalence antigen Joa was first described in 
197213 and later shown to have a phenotypic association 
with Gya and Hy  because RBCs with either the Gy(a–) phe-
notype or the Hy– phenotype are also Jo(a–).14,15 Joa was 
assigned a number in the ISBT Series of High Incidence An-
tigens before its association with Gya and Hy was realized.7 
When  Joa  was shown to reside on the Gregory glycoprotein 
by immunoblotting,16 it was not placed in the Gregory col-
lection but it was promoted directly to the Dombrock blood 
group system.17,18 Another high-prevalence antigen, Jca, was 
shown to be associated with Gya and Hy,19 and although it 
was reported to be the same as Joa,20 there remained some 
doubt and an ISBT number was not assigned to Jca. On the 
basis of subsequent work, this doubt was justified (see later 
discussion).21
 In 1992, Banks and coworkers22 revealed that in addi-
tion to being Hy– and Jo(a–), Gy(a–) RBCs were Do(a–b–). 
Thus, it was shown that RBCs with the Gy(a–) phenotype 
are the null phenotype of the Dombrock blood group sys-
tem.23 After this discovery, Gya, Hy, and Joa  were assigned 
ISBT numbers in the Dombrock blood group system (Table 
2).17,18
Dombrock Glycoprotein
 Antigens in the Dombrock blood group system are car-
ried on a GPI-linked glycoprotein.12,16,24 The Dombrock gly-
coprotein has an apparent Mr of approximately 47,000 to 
58,000 in SDS-PAGE under nonreducing conditions.12,23 
In the membrane-bound form, the Do glycoprotein has 
Table 2. ISBT terminology for the Dombrock (014) blood group 
system antigens
Traditional 





Gya DO3 014003 206001; 
900005
Hy DO4 014004 206002; 
900011




five potential N-linked glycosylation sites and four or five 
cysteine residues.25 The susceptibility of some Do antigens 
to sulfhydryl compounds suggests that the tertiary con-
formation of the glycoprotein is dependent on disulfide 
bonds.
 The Do glycoprotein is expressed primarily on eryth-
roid cells in adult bone marrow and in fetal liver. Expres-
sion may also occur in the lymph nodes (on lymphocytes), 
testes, spleen, and fetal heart. Although the Do glycoprotein 
is a member of the mono-ADP-ribosyltransferase family, no 
enzyme activity has been demonstrated on the RBC. ADP-
ribosyltransferases catalyze the transfer of ADP-ribose from 
NAD+ to a specific amino acid in a target protein that modu-
lates protein function. ADP-ribosylation can be reversed by 
ADP-ribosyl hydrolases, which remove the ADP-ribose and 
restore protein function.26,27 Thus, Do may be involved in 
the regulation of cellular protein function.
Dombrock Antigens
 The characteristics of antigens in this system are sum-
marized in Table 3. The susceptibility and resistance of an-
tigens in the Dombrock system to treatment of RBCs with 
various proteolytic enzymes and DTT, and their absence 
from paroxysmal nocturnal hemoglobinuria (PNH) type III 
RBCs,24 can be used to aid the identification of antibodies to 
Dombrock antigens.
Dombrock Antibodies
 Studies involving the Dombrock blood group system 
have been hampered by the paucity of reliable monospe-
cific antisera. Antibodies in the Dombrock blood group sys-
tem can be difficult to identify. This is especially true for 
the differentiation of anti-Hy from anti-Joa. As will be de-
scribed later, determination of the molecular basis associ-
ated with Hy and Joa has provided an explanation for this 
Table 3. Characteristics of antigens in the Dombrock blood group 
system
Resistant to papain or ficin treatment of antigen-positive RBCs. Often the 
reactivity is enhanced.
Sensitive to trypsin treatment of antigen-positive RBCs.
Doa, Dob, Gya, Hy, DOYA, and DOMR are sensitive to DTT (200 mM) 
treatment of antigen-positive RBCs. Joa is variably affected by such treat-
ment. All antigens are resistant to treatment of antigen-positive RBCs 
with 50 mM DTT.
Weakened by α-chymotrypsin or AET treatment of antigen-positive RBCs.
Expressed on cord RBCs; although Gya, Hy, and Joa may be weaker than 
on RBCs from adults.
Absent from PNH III RBCs.
Some variation in expression on different RBCs and on RBCs from differ-
ent people.
Carried on a mono-ADP-ribosyltransferase (ART-4), a GPI-linked protein.
Doa, Dob, Hy, and Joa are not highly immunogenic.
AET = 2-aminoethylisothiouronium bromide; GPI = glycosylphos-
phatidylinositol; PNH = paroxysmal nocturnal hemoglobinuria.
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particular difficulty. Common characteristics of antibodies 
to Dombrock blood group system antigens are summarized 
in Table 4.
Clinical Importance
 Although transfusion reactions caused by anti-Doa 
or anti-Dob have been reported,28–37 they may be under- 
reported. One reason is that events usually associated with 
transfusion reactions may not be observed. For example, 
the DAT is often negative, no antibody is eluted from the 
patient’s RBC samples after transfusion, there is no lag 
phase in the antibody reactivity, and no increase in titer of 
the antibody is observed. However, in our experience, the 
provision of Do(a–) or Do(b–) blood as predicted by DNA 
analysis has improved RBC survival in patients with the 
corresponding antibody who receive chronic transfusions. 
At least one anti-Hy has caused biphasic destruction of Hy+ 
RBCs38; other examples of anti-Hy, and anti-Gya and anti-
Joa, have caused moderate transfusion reactions. In the ab-
sence of Gy(a–) blood, Hy– blood has been a suitable sub-
stitute (personal observations). Some anti-Gya appear to 
be benign: 10 Gy(a+) units were transfused to a man with 
anti-Gya without adverse consequences.39 Antibodies in the 
Dombrock blood group system typically do not cause clini-
cal HDN, although RBCs of some antigen-positive babies 
were positive in the DAT. One baby of a mother with anti-
DOMR was born icteric and required phototherapy.40
The DO Gene
 For some time, it has been known that DO is located on 
the short arm of chromosome 12 (Fig. 1).41 In silico analysis 
aided in identification of a candidate DO gene, which has 
been cloned and sequenced (GenBank accession number; 
AF290204).25 DO is the first blood group gene to be cloned 
by an in silico approach.42
 The DO gene is identical to ART4, described in 1997 
(GenBank accession number X95826),43 and has been re-
named DO (GenBank accession number NM_021071, 
AF290204). The data sets for the chromosomal arms of 
ART3 and ART4 were inadvertently switched,43 so ART4 
was incorrectly reported to reside on the long arm of chro-
mosome 12. Had it not been for this switch, it is likely that 
ART4 would have been recognized as the DO gene in 1997! 
Although the original publication for ART4 did not include 
exon 1,43 the entire sequence of ART4 is identical to DO (F. 
Koch-Nolte, personal communication). Cloning and se-
quencing of DO allowed the determination of the molecular 
basis associated with various Do phenotypes (see later dis-
cussion) and led to PCR-based assays to screen for antigen-
negative donors and identify new alleles.
 The DO gene consists of three exons distributed over 14 
kilobase pairs (kbp) of DNA (Fig. 1). The messenger RNA, 
which consists of 1.1 kbp, is predicted to encode a protein of 
314 amino acids that has both a signal peptide and a GPI-
anchor motif (Fig. 1).25 Both these are cleaved and not pres-
ent in the membrane-bound form of Do. The DO*B allele 
encodes an Arg-Gly-Asp (263-RGD-265) motif. RGD mo-
tifs within adhesive ligands are commonly involved in cell-
to-cell interactions involving integrin binding.44 However, 
because the DO*A allele, and the chimpanzee DO (pDO) 
homolog, encode asparagine (N) instead of aspartic acid 
(D),25,45 it is unlikely that the RGD motif encoded by the 
DO*B allele is a critical one.46
Molecular Basis of Antigens and Phenotypes
The Polymorphic Doa (DO1) and Dob (DO2) Antigens
 The common forms of DO*A and DO*B alleles differ in 
three nucleotide positions in exon 2. Two are silent nucle-
otide changes (378C>T, Tyr126Tyr; 624T>C, Leu208Leu); 
the third is a missense change (793A>G, Asn265Asp), which 
encodes, respectively, Doa and Dob (Table 5).25 These three 
nucleotide changes can be readily differentiated by PCR-
RFLP, using DraIII for 378C>T,47 MnlI for 624T>C,47 and 
BSeRI for 793A>G.49 Allele-specific PCR also can be used to 
differentiate DO*A from DO*B.50 The ability to distinguish 
DO*A from DO*B makes it feasible to predict the Do type of 
patients and blood donors. This is a tremendous advantage 
Fig. 1 Diagram of DO, its organization, and the Do glycoprotein. (A) 
Location (12p12.3) of DO on the short arm of chromosome 12. (B) 
The organization of the three DO exons. (C) The Do protein with signal 
peptide at the amino terminus and glycosylphosphatidylinositol (GPI)- 
anchor motif at the carboxyl terminus.
Table 4. Characteristics of antibodies to Dombrock antigens 
Usually IgG.
React optimally by column agglutination technology or by the IAT using 
papain- or ficin-treated RBCs.
Usually weakly reactive.
Do not bind complement.
Stimulated by pregnancy and by transfusion.
Usually present in sera containing other alloantibodies. The exception is 
anti-Gya, which often occurs as a single specificity.
Often deteriorate in vitro and fall below detectable levels in vivo.
Have not caused clinical HDFN (positive DAT only) but have caused 
transfusion reactions.
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because, owing to the paucity of reliable reagents, screening 
for large numbers of Do(a–) or Do(b–) blood donors using 
classical hemagglutination methods has not been feasible.
The High-Prevalence Gya (DO3) Antigen
 An absence of Gya, in addition to an absence of all an-
tigens in the Dombrock blood group system, defines the 
Donull [Gy(a–)] phenotype. To date, DO has been described 
to be silenced by five molecular bases (Table 6). Two of 
them, a mutation in the donor splice site52 and a mutation 
in the acceptor splice site,51 lead to outsplicing of exon 2. 
The third mechanism is a nonsense change in a DO*A-HA 
allele [350C; 378T (DO*B); 624T (DO*A); 793A (DO*A), 
see later section].52 A fourth proband has a deletion of eight 
nucleotides within exon 2 that leads to a frameshift and a 
premature stop codon,53 and the fifth is attributable to an 
amino acid substitution of Phe62 to Ser.54
The High-Prevalence Hy (DO4) Antigen
 The nucleotide change associated with Hy+/Hy– phe-
notypes is 323G>T in exon 2, which is predicted to encode 
Gly108Val. The change is associated with the absence of Hy 
and is on an allele carrying 378C (DO*A), 624C (DO*B), and 
793G (DO*B) (Table 5). Its association with 793G (265Asp) 
explains why RBCs with the Hy– phenotype are invariably 
Do(a–b+). There are two forms of the allele giving rise to 
the Hy– phenotype, one with 898G (300Val) and the other 
with 898C (300Leu). Nucleotide 898C (300Leu) is present 
on the allele encoding the wild-type Hy+. As the 898G allele 
was present in the sister of the original Hy– proband it was 
named HY1, and the HY allele with the wild-type nucleotide 
898C, HY2.21 Testing with one potent example of anti-Joa 
showed that some Hy– RBCs express Joa very weakly.56
The High-Prevalence Joa (DO5) Antigen
 A single nucleotide change of 350C>T in exon 2 is 
predicted to encode isoleucine at amino acid residue 117. 
Nucleotide 350T is associated with the absence of the Joa 
antigen and is predominantly on an allele carrying 378T 
(DO*B), 624T (DO*A), and 793A (DO*A) (Table 5). The 
genotype of people whose RBCs have the Jo(a–) pheno-
type can be DO*JO/JO or DO*HY/JO.21 Its association with 
793A (265Asn) explains why most RBCs with the Jo(a–) 
phenotype are Do(a+b–) (Fig. 2). RBCs from individuals 
with the DO*HY/JO genotype will type Do(a+b+w).
The Jca Antigen
 DNA analysis on four samples that had been original-
ly typed as Jc(a–) revealed a combination of DO*HY and 
DO*JO alleles (DO*HY1/HY1; DO*HY1/HY2; DO*HY1/
JO; DO*JO/JO). These results show that Jca is not a dis-
crete antigen.21
Fig. 2 Diagram showing amino acids associated with the various Do 
phenotypes. The effect of the amino acid changes associated with 
Hy–, Jo(a–), DOYA–, and DOMR– phenotypes on the other Do anti-
gens is given under each stick figure. The figures for the DOYA– and 
DOMR– phenotypes are each based on the only known proband.
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†Reference allele DO*01 (AF290204; shaded) encodes Doa, Gya, 
Hy, Joa, DOYA, and DOMR antigens.See Table 6 for alleles that 
result in the Gy(a–) phenotype.
‡ISBT proposed allele name pending ratification June 2010.
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†Changes from the reference allele (GenBank accession number 
AF290204) are given.
‡The background for this allele is actually DO*A-HA (378T, 524T, 
793A).55
§ISBT proposed allele name pending ratification June 2010.
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The High-Prevalence DOYA (DO6) Antigen
 The nucleotide change associated with DOYA+/DOYA– 
phenotypes is DO*A.547T>G in exon 2, which is predicted 
to change Tyr183 to Asp (Table 5). In the DOYA– Turkish 
Kurd proband, this change silenced the expected Doa, so her 
RBCs typed Do(a–b–). They also have a weakened expres-
sion of Gya, Hy, and Joa  (Fig. 2).57
The High-Prevalence DOMR (DO7) Antigen
 The novel nucleotide changes associated with DOMR+/
DOMR– phenotypes are 431C>A and 432C>A, which are 
predicted to encode Ala(GCC)144Glu(GAA) (Table 5). The 
change is associated with the absence of the DOMR anti-
gen and is on a DO*B-WL allele (see later section). Its as-
sociation with 793G (265Asp) explains why RBCs with the 
DOMR– phenotype are Do(b+), albeit weakly. RBCs from 
the DOMR– Brazilian Black proband have a weakened ex-
pression of Gya, Hy, and Joa (Fig. 2).40
Other DO Alleles
 Testing of DNA from Blacks from Brazil or the Congo 
led to the recognition of additional DO alleles. These are 
DO*A-HA,55 DO*A-SH,58 DO*A-WL,59 DO*B-SH,55 DO*B-
WL,58 DO*B-SH-Q149K,60 and DO*B-I175N (it is possible 
that this last allele could be on a DO*B-WL background) 
(Table 7).60 The initials used in these allele names are de-
rived from the initials of investigators who reported them. 
Information is lacking about the nature of the Do glycopro-
tein or antigenic expression, if any, encoded by these alleles. 
These alleles are not known to encode novel antigens.
Table 7. DO alleles, including some that were described only at the DNA level
Allele name nt (aa) nt (aa) Nt nt nt (aa) nt (aa) nt (aa)
ISBT Other 323 (108) 350 (117) 378 624 793 (265) 898 (300) Other
DO*01 DO*A G (Gly) C (Thr) C T A (Asn) C (Leu)
DO*01.–05 DO*JO G (Gly) T (Ile) T T A (Asn) C (Leu)
DO*01.–06 DOYA G (Gly) C (Thr) C T A (Asn) C (Leu) 547T>G (Tyr183Asp)
DO*A-HA† G (Gly) C (Thr) T T A (Asn) C (Leu)
DO*A-SH† G (Gly) C (Thr) C C A (Asn) C (Leu)
DO*A-WL† G (Gly) C (Thr) C T A (Asn) G (Val)
DO*02 DO*B G (Gly) C (Thr) T C G (Asp) C (Leu)
DO*02.–04 DO*HY1 T (Val) C (Thr) C C G (Asp) G (Val)
DO*02.–04 DO*HY2 T (Val) C (Thr) C C G (Asp) C (Leu)
DO*02.–07 DOMR G (Gly) C (Thr) T C G (Asp) G (Val) 431C>A and 432C>A (Ala144Glu)
DO*B-SH† G (Gly) C (Thr) C C G (Asp) C (Leu)
DO*B-SH-Q149K† G (Gly) C (Thr) C C G (Asp) C (Leu) 445C>A (Gln149Lys)
DO*B-WL† G (Gly) C (Thr) T C G (Asp) G (Val)
DO*B-I175N† G (Gly) C (Thr) T C G (Asp) C (Leu) 524T>A (Ile175Asn)
†Alleles defined only through DNA-based assay; not investigated serologically.
aa = amino acid; nt = nucleotide.
 Chapel-Fernandes and coworkers60 measured the ex-
pression of various Do proteins on transduced K562 cells by 
flow cytometry using monoclonal anti-Do. They report that 
the protein encoded by DO*B-SH, DO*B-WL, and DO*B-
SH-Q149K alleles was expressed in lower copy number than 
the protein encoded by DO*B or DO*B-I175N alleles. This 
finding may provide insights into the variable expression of 
Dob on RBCs.
DO and Anthropology
 The chimpanzee DO allele has the human wild-type 
nucleotides at positions 323, 350, and 898 and has 378T 
(DO*B), 624C (DO*B), and 793A (DO*A).21 This sequence 
has not been found in humans and does not provide an in-
sight as to the primordial DO gene. The sequence of the allele 
from three unrelated chimpanzees was identical (GenBank 
accession numbers AF373016, AF373017, and AF374727).
Transfection of DO cDNA
 Cells transfected with DO cDNA have been used to study 
expression levels of Do.25,60 Cells transfected with DO cDNA 
have also been used as an immunogen to produce several 
monoclonal antibodies (MoAbs). Two MoAbs, MIMA-52 
that recognizes a DTT-sensitive epitope and MIMA-53 that 
recognizes a DTT-resistant epitope, strongly agglutinate 
RBCs from humans [except Gy(a–)] and other great apes 
but not from lesser apes, old world monkeys, new world 
monkeys, prosimians, rabbits, dogs, sheep, or mice.45 Three 
other MoAbs (MIMA-64, MIMA-73, and MIMA-98) agglu-
tinated RBCs from humans, chimpanzees, greater apes, and 
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lesser apes but not RBCs from the other animals (unpub-
lished observations). A homolog of the DO has been found 
in mouse,43 and thus the lack of reaction with mouse RBCs 
indicates that the specific epitope recognized by the MIMA 
anti-Do is restricted to apes.61
Expression of Dombrock Antigens
 The molecular basis associated with Hy– and Jo(a–) 
phenotypes was determined only after numerous samples 
were analyzed. During this analysis, it became clear that 
RBC samples had been misidentified. The most significant 
was that of SJ after whom the Joseph phenotype and Joa 
antigen were named. Surprisingly, DNA from SJ typed 
DO*HY1/HY2 and DNA from her Hy+ brother was DOHY2/
DO*B.21 Thus, any “anti-Joa” that was identified by using SJ 
RBCs may actually be anti-Hy. The use of such RBCs and 
antibodies as reagents has led to the inadvertent incorrect 
labeling of reagents. To correctly identify anti-Hy and anti-
Joa, RBCs whose type has been predicted by DNA analysis 
should be used. The various possible combinations and ex-
pected antigen expression are given in Table 7. RBCs from 
people with DO*JO/JO or DO*JO/HY genotypes will have 
the same phenotype, although the latter may have a slightly 
weaker expression of Hy.
 The close proximity of amino acids associated with Hy 
(residue 108) and Joa (residue 117) antigen expression may 
explain why Hy– RBCs lack or have an extremely weak ex-
pression of Joa and why Jo(a–) RBCs have a weak expres-
sion of Hy (Fig. 2). The two critical residues are separated 
by only eight amino acids, which is within the range of an 
antigenic determinant.62,63 The reason for the weak expres-
sion of Gya  on Hy– RBCs, the weak expression of Dob on 
RBCs with the Hy– phenotype, and the weak expression of 
Doa on RBCs with the Jo(a–) phenotype is still not under-
stood but likely involves conformation or the effect of steric 
hindrance or charge on the conformation. Interestingly, the 
amino acid changes involved with an absence of DOYA or 
DOMR also weaken other Do antigens (Fig. 2).
 It is apparent that the immune response in different 
people with the same Dombrock phenotype varies. One 
possibility is that Hy– patients may produce anti-Doa in 
addition to anti-Hy, and Jo(a–) patients may produce anti-
Dob in addition to anti-Joa. Furthermore, a patient with a 
Jo(a–) phenotype and a DO*HY/JO genotype should have 
RBCs that type Do(a+wb+w) Gy(a+) Hy(a+w) Jo(a–) and 
thus would be expected to make only anti-Joa. The results 
of DNA analysis of serologically identified samples with 
unusual Do phenotypes provide an explanation for the di-
versity of typing results in antibody producers and for the 
diversity of the reactivity of their plasma and serum of their 
immune response.
Conclusions
 Determination of the molecular basis underlying the 
antigens in the Dombrock blood group system has several 
advantages and has changed practice in transfusion medi-
cine. The first, as outlined earlier, is the possibility of using 
RBCs with a bona fide antigen profile in antibody identifi-
cation studies. The second advantage is to predict the phe-
notype of patient RBCs to aid in the antibody identification 
process; the third is the ability to type donors for DO*A and 
DO*B and thereby select Do(b–) RBCs for transfusion to a 
patient who has or has had anti-Dob. Yet another value is 
to be able to type donors whose RBCs are used in antibody 
identification panels.64 This is, perhaps, the first instance 
in which DNA analysis is more reliable than hemaggluti-
nation. This is because the antibodies (especially anti-Doa 
and anti-Dob) are rarely available as a single specificity with 
strength and volume to make accurate typing possible.
 There is no known disease entity associated with the 
Doa form of the Dombrock glycoprotein (RGD→RGN) nor, 
indeed, with an absence of the entire glycoprotein [Gy(a–)]. 
The presence of RGN in the chimpanzee homolog21 suggests 
that this, and not RGD, may be the primordial sequence. Ex-
pression of Dombrock and other ectoenzymes (Kell and Yt) 
on RBCs may provide a readily transportable steady-state 
level of these enzymes for tissues in the vascular space.
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